NASDAQ:IMRX Immuneering Q2 2025 Earnings Report $4.07 +0.04 (+0.99%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$4.09 +0.02 (+0.39%) As of 10/2/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immuneering EPS ResultsActual EPS-$0.40Consensus EPS -$0.40Beat/MissMet ExpectationsOne Year Ago EPSN/AImmuneering Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmuneering Announcement DetailsQuarterQ2 2025Date8/13/2025TimeBefore Market OpensConference Call DateWednesday, August 13, 2025Conference Call Time12:00AM ETUpcoming EarningsImmuneering's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Immuneering Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: Glaukos (GKOS) and Immuneering (IMRX)October 3 at 5:16 PM | theglobeandmail.comImmuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)October 2 at 9:00 AM | globenewswire.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 3 at 1:00 AM | Altimetry (Ad)Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic CancerSeptember 28, 2026 | finance.yahoo.comImmuneering Corporation Presents Data At 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib?S Mechanisms Designed to Extend Survival in Pancreatic CancerSeptember 28, 2026 | marketscreener.comMImmuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic CancerSeptember 28, 2026 | globenewswire.comSee More Immuneering Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immuneering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuneering and other key companies, straight to your email. Email Address About ImmuneeringImmuneering (NASDAQ:IMRX) is a clinical-stage biotechnology company focused on developing medicines for cancer patients with limited treatment options. The company’s research centers on the mitogen-activated protein kinase (MAPK) pathway, a cellular signaling network frequently altered in solid tumors, including cancers driven by RAS mutations. Immuneering’s lead product candidate is IMM-1-104, an oral therapy designed to provide deep and sustained inhibition of the MAPK pathway while using intermittent exposure to help normal cells recover. The candidate is being evaluated in clinical studies for advanced solid tumors, including pancreatic cancer. The company is also developing IMM-6-415, a next-generation investigational treatment intended for RAS-mutant cancers. Founded in 2008 and headquartered in Cambridge, Massachusetts, Immuneering became a publicly traded company in 2021. Its programs are being developed through clinical research and collaborations with treatment centers, primarily for patients with advanced cancers in the United States and other regions where its trials are conducted. Benjamin Zeskind, Ph.D., is a co-founder and has served as the company’s chief executive officer.View Immuneering ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
